Mechanism of action of OPC-8490 in human ventricular myocardium

• Published in: Circulation (New York, N.Y.) N.Y.), 1996-02, Vol.93 (4), p.817-825
• Main Authors: FOCACCIO, A, PEETERS, G, MOVSESIAN, M, RODEN, R, EKI, Y, KRALL, J, BRISTOW, M. R
• Format: Article
• Language: English
• Subjects: 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors; Action Potentials - drug effects; Adult; Azetidines - pharmacology; Biological and medical sciences; Cardiotonic agents; Cardiotonic Agents - pharmacology; Cardiovascular system; Cyclic Nucleotide Phosphodiesterases, Type 3; Enoximone - pharmacology; Heart - drug effects; Heart - physiology; Heart Failure - physiopathology; Heart Ventricles - drug effects; Humans; In Vitro Techniques; Ion Channels - drug effects; Medical sciences; Middle Aged; Milrinone; Myocardial Contraction - drug effects; Pharmacology. Drug treatments; Phosphodiesterase Inhibitors - pharmacology; Piperazines - pharmacology; Pyridones - pharmacology; Quinolones - pharmacology; Sotalol - pharmacology; Ventricular Function; Veratridine - pharmacology
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.93.4.817

The quinolinone compounds OPC-8212 (vesnarinone), OPC-18790, and OPC-8490 are members of a family of unique positive inotropic compounds that have no positive chronotropic effects. In subjects with heart failure, the prototypic compound OPC-8212 may reduce morbidity and mortality at low doses but increase mortality at high doses. To further characterize the inotropic mechanism(s) of action of these compounds, we investigated the effects of OPC-8490, a water-soluble quinolinone, on the inotropic response, inhibition of phosphodiesterase (PDE), and action potential in human ventricular myocardial preparations. In isolated right ventricular trabeculae and membranes prepared from left ventricular myocardium, OPC-8490 produced dose-related positive inotropic effects, inhibited type III PDE activity, and prolonged action potential. Comparative experiments with other PDE inhibitors, sodium channel agonists, and potassium channel antagonists indicated that the positive inotropic effects are due to PDE inhibition, whereas the action potential effects of OPC-8490 are due to effects on ion channels. We conclude that OPC-8490 produces selective positive inotropic effects because of type III PDE inhibition combined with ion channel effects, with the latter property inhibiting the positive chronotropic response usually associated with agents that increase intracellular cAMP concentrations.